All News

A one-size-fits-all approach to alternative payment models (APMs) often isn’t very fair to community practices, said Miriam Atkins, MD, FACP, president of the Community Oncology Alliance.

This year’s top content in the Duchenne muscular dystrophy (DMD) space focused on a novel gene therapy approval, the high cost of care for this genetic disorder, and steps forward in other treatments.

A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.

This year’s most-read respiratory articles explored a variety of topics, including the effects of marijuana and vaping on the lungs.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

A study investigating potential subtypes of idiopathic hypersomnia (IH) found that patients with IH who experience unrefreshing naps have less fragmented sleep compared with those who take refreshing naps, suggesting unrefreshing naps could serve as a supportive IH clinical feature.

The top-read topics in HIV for 2023 included dried blood tests for HIV, people with HIV facing stigmas, and vitamin D supplementation in women with HIV.

The FDA approved the first test to assess opioid addiction risk; Americans are using more cold and allergy medicines to mask any related symptoms to return to work and social gatherings, but may be overtreating themselves in the process; Rite Aid will be banned from using artificial intelligence–powered facial recognition technology for 5 years under a proposed Federal Trade Commission settlement.

Areas where fireworks were legal had slightly higher odds of firework-related ocular trauma in their residents.

This year’s top 5 most-listened to podcasts included topics on digital health solutions, cardiology, value-based care initiatives, and oncology.

The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.

Baricitinib is more commonly prescribed by dermatologists for patients with alopecia in the United States and is projected to maintain a substantial market lead over ritlecitinib.

Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.

A new survey from the National Alliance of Healthcare Purchaser Coalitions found that employers are planning to place a larger focus on obesity management, women’s health, and health equity in 2024 and beyond.

Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.

From the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus meeting, held in October, expert interviews and insightful updates on the Inflation Reduction Act, gene therapy affordability and access, and the 340B Drug Pricing Program comprise the conference highlights.

Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.

Our top conference coverage of 2023 covered a range of topics, including cardiovascular disease, heart failure, breast cancer, and chronic lymphocytic leukemia.

CDC warns of rapid spread of new COVID-19 JN.1 subvariant amidst holiday travel; drugmakers and physicians experience significant drops in reputation; HHS urges action amidst soaring drop in child enrollment for Medicaid plans.

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.

Maternal vaccination during pregnancy may provide important protection before infants are eligible to receive a vaccine, a study suggests.

These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.

Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.

The human monoclonal antibody known as tralokinumab-ldrm was tested and approved as a safe, effective treatment for pediatric patients with atopic dermatitis aged 12 to 17 years old.

This year’s most-read asthma articles included the impact of extreme weather events, neighborhood determinants of health, and other risk factors for asthma exacerbations.

Patients aged 80 years and older with colorectal cancer (CRC) could have an improved prognosis at the completion of adjuvant chemotherapy.

This year’s most-read articles on inflammation explored predictive biomarkers, medication acceptance, the impacts of long COVID-19, and more.

Posters presented at the American Society of Hematology Annual Meeting and Exposition identified factors associated with reducing risk and improving survival in patients with polycythemia vera (PV).